LifeMD, Inc. LFMD R2K
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 17.7% over 5 years.
- Profit CAGR of 43.8% over 5 years.
CONS
- Trading 71.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LFMD LifeMD, Inc. R2K | 4.28 | - | $206.99M | - | -30.60% | - | 17.69% | 43.84% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.70M | 2.70M | 3.13M | 4.30M | 9.09M | 11.01M | 18.20M | 22.31M | 24.95M | 29.04M | 30.46M | 31.41M | 33.13M | 35.95M | 38.61M | 44.14M | 50.66M | - | - | 50.89M | 62.22M | 60.17M | 7.08M | 50.16M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.14M | 7.43M | 7.41M | 4.23M | 5.93M |
| Gross Profit | 52.31K | 143.34K | 127.45K | 93.86K | 214.06K | 187.85K | 205.90K | 303.09K | 526.27K | 996.23K | 79.73K | 474.99K | 1.52M | 1.25M | 1.50M | 2.06M | 1.99M | 2.04M | 2.45M | 2.97M | 7.40M | 9.33M | 14.99M | 18.19M | 19.85M | 23.79M | 25.82M | 26.70M | 28.91M | 31.40M | 33.83M | 39.54M | 45.64M | - | - | 42.75M | 54.79M | 52.76M | 2.85M | 44.24M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.93M | 55.69M | 54.73M | 9.07M | 53.17M |
| Operating Income | -168.67K | -177.64K | -75.38K | -132.94K | 7.83K | -17.17K | 17.94K | -105.10K | -153.63K | -207.70K | -401.79K | -380.30K | -273.57K | -279.31K | -938.45K | -438.63K | -563.37K | -833.16K | -973.71K | -1.74M | -3.22M | -20.53M | -11.92M | -16.13M | -12.59M | -13.11M | -12.90M | -7.07M | -2.85M | -4.90M | -4.57M | -6.17M | -6.31M | - | - | -1.18M | -906.77K | -1.97M | -6.22M | -8.93M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 509.69K | 2.88M | -133.33K | -6.22M | -6.93M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 558.60K | - | 626.27K | 663.03K | 262.46K | -190.79K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.65M | -1.57M | -3.39M | -6.03M | -8.87M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 169.48K | 0 | - | 169.13K | -123.41K | 0 |
| Net Income | -139.37K | -140.94K | -71.50K | -103.90K | 1.67K | -21.03K | 8.12K | -62.05K | -199.98K | -226.65K | -1.04M | 737.49K | -679.06K | 627.28K | -1.05M | -548.98K | -663.75K | -818.10K | -943.80K | -2.39M | -3.38M | -20.62M | -11.60M | -16.83M | -14.35M | -13.30M | -13.02M | -7.28M | -4.01M | -6.73M | -6.12M | -6.77M | -6.88M | - | - | -183.78K | -2.07M | -3.81M | 19.96M | -8.87M |
| Diluted EPS | - | - | - | - | 31,363,306.00 | 30,650,000.00 | 30,650,000.00 | 32,010,375.00 | -0.01 | -0.01 | - | 0.02 | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.02 | -0.06 | -0.10 | 0.41 | -0.20 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 42.52K | 12.47M | 37.29M | - | 119.03M | 152.55M | 154.82M | 194.06M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 18.67M | 18.90M | 21.44M | 27.71M |
| Gross Profit | 473.87K | 627.06K | 541.31K | 971.09K | 3.29M | 2.66M | 6.33M | 9.94M | 28.43M | - | 100.37M | 133.65M | 133.38M | 166.34M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 140.05M | 148.14M | 153.79M | 174.01M |
| Operating Income | -540.02K | -546.41K | -530.88K | -262.22K | -1.17M | -1.23M | -2.06M | -2.89M | -57.82M | - | -39.69M | -14.49M | -20.40M | -7.67M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -35.92M | -7.89M | -14.21M | -1.52M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 2.18M | 1.36M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -44.66M | -17.41M | -22.58M | -10.19M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 360.70K | 428.00K | 598.00K | 45.72K |
| Net Income | -445.65K | -268.26K | -460.49K | -61.99K | -1.11M | -1.21M | -1.24M | -3.14M | -58.65M | - | -45.54M | -20.60M | -21.41M | 14.35M |
| Diluted EPS | - | - | - | - | -0.03 | -0.03 | - | - | - | - | -1.57 | -0.70 | -0.53 | 0.25 |
| R&D Expense | - | - | - | 23.93K | - | - | - | - | - | - | - | - | - | - |
Compounded Sales Growth
| 5 Years: | 17.69% |
| 1 Year: | -1.40% |
Compounded Profit Growth
| 5 Years: | 43.84% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -64.95% |
| 6 Months: | +8.91% |
| 3 Months: | +60.30% |
| 1 Month: | -3.39% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Sep 2012 | Dec 2012 | Dec 2013 | Dec 2014 | Sep 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 369.69K | 551.45K | 175.22K | - | 448.47K | 789.82K | 1.26M | 2.62M | 3.45M | 13.40M | - | 25.67M | 58.48M | 76.10M | 70.41M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.31M | 42.60M | 52.37M | 51.83M |
| Cash & Equivalents | 33.50K | 163.18K | 98.93K | 155.06K | 75.50K | 73.86K | 232.98K | 182.56K | 141.38K | 180.09K | 1.11M | 9.18M | - | 3.96M | 33.15M | 32.65M | 36.79M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.70M | 2.76M | 2.80M | 2.77M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.83M | 5.28M | 10.46M | 9.31M |
| Total Liabilities | - | - | 234.70K | 355.96K | 314.72K | - | 267.48K | - | 640.97K | 1.80M | 4.58M | 14.22M | - | 32.97M | 52.91M | 83.65M | 47.25M |
| Current Liabilities | - | - | 187.10K | 325.56K | 301.52K | - | 267.48K | 1.15M | 640.97K | 1.19M | 3.98M | 13.93M | - | 31.37M | 34.78M | 67.40M | 41.57M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.93M | 9.89M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.13M | 18.93M | 24.93M | 6.32M |
| Total Equity | -282.98K | - | 135.00K | 195.49K | -139.50K | - | 100.08K | -355.17K | 881.92K | 897.70K | -988.18K | -2.30M | - | -6.83M | 3.51M | -9.08M | 23.16M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.55M | 38.36M | 42.29M | 46.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -229.73K | -259.07K | 33.44K | -295.12K | -407.91K | -817.22K | -905.52K | 251.41K | -12.13M | - | -22.94M | 8.82M | 17.51M | 8.28M |
| Investing Cash Flow | - | - | - | - | - | - | 141.44K | -100.00K | -798.14K | - | -13.91M | -8.73M | -11.54M | 6.91M |
| Financing Cash Flow | 295.15K | 315.20K | -113.00K | 325.35K | 357.49K | 776.03K | 802.79K | 775.12K | 21.00M | - | -528.20K | 29.10M | -4.12M | -13.41M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | -12.89M | -8.73M | -8.20M | -9.52M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | -35.83M | 86.95K | 9.31M | -1.24M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -37.37M | 29.19M | 1.86M | 1.78M |
| Share Buybacks | - | - | - | - | - | 76.65K | - | - | - | - | - | - | - | 270.00K |
| Dividends Paid | - | - | - | - | - | - | - | - | - | 871.48K | 3.11M | 3.11M | 3.11M | 3.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | 14,883.9% | 79.7% | 76.2% | - | 84.3% | 87.6% | 86.2% | 85.7% |
| Operating Margin % | - | - | - | - | - | - | -4,836.3% | -23.2% | -155.0% | - | -33.3% | -9.5% | -13.2% | -4.0% |
| Net Margin % | - | - | - | - | - | - | -2,918.6% | -25.2% | -157.3% | - | -38.3% | -13.5% | -13.8% | 7.4% |
| ROE % | -330.1% | -137.2% | 330.1% | -61.9% | 311.8% | -136.7% | -138.2% | 317.5% | 2,547.8% | - | 666.7% | -587.6% | 235.7% | 62.0% |
| ROCE % | -295.7% | -241.9% | 420.3% | -144.9% | 324.7% | -197.2% | -144.4% | 546.0% | 10,920.8% | - | 695.2% | -61.1% | -234.6% | -26.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.81% | 2.81M | $12.02M |
| 2 | Vanguard Capital Management LLC | 3.44% | 1.66M | $7.12M |
| 3 | Royce & Associates LP | 2.48% | 1.20M | $5.14M |
| 4 | Renaissance Technologies, LLC | 2.31% | 1.12M | $4.79M |
| 5 | State Street Corporation | 2.22% | 1.08M | $4.60M |
| 6 | Federated Hermes, Inc. | 2.11% | 1.02M | $4.36M |
| 7 | Geode Capital Management, LLC | 2.11% | 1.02M | $4.36M |
| 8 | Prescott Group Capital Management, L.L.C. | 1.85% | 895.42K | $3.83M |
| 9 | Brc Group Holdings, Inc. | 1.80% | 871.58K | $3.73M |
| 10 | Susquehanna International Group, LLP | 0.96% | 465.19K | $1.99M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LFMD